Unknown PHASE4 INTERVENTIONAL 2-arm NCT05393505

Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection (FRANCiS-NF)

Fast-track Absolute Neutrophil Count in Suspected Neutropenic Fever (The FRANCiS-NF Trial): A Single-centre, Pragmatic, Open-label, Randomised, Controlled Trial

Sponsor: Queen Mary Hospital, Hong Kong

Conditions Neutropenic Fever

Interventions Amoxicillin Clavulanate Antibiotic Levofloxacin Meropenem Injection

Updated 7 times since 2022 Last updated: Dec 5, 2022 Started: Oct 24, 2022 Primary completion: Mar 14, 2025 Completion: Jun 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Neutropenic Fever and is currently ongoing. Queen Mary Hospital, Hong Kong leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Aug 2025 — Present [monthly]

Unknown PHASE4

Status: Recruiting → Unknown
Sep 2024 — Aug 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Jan 2023 — Jul 2024 [monthly]

Recruiting PHASE4
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE4

▶ Show 2 earlier versions

Jul 2022 — Dec 2022 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Jun 2022 — Jul 2022 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Queen Mary Hospital, Hong Kong
The University of Hong Kong

Data source: The University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hong Kong, Hong Kong